Turkish Journal of Gastroenterology
Liver - Original Article

Safety and Effectiveness of Essential Phospholipids Paste in Patients with Non-alcoholic Fatty Liver Disease or Viral Hepatitis

1.

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia, Moscow, Russia

2.

A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia, Moscow, Russia

3.

Clinical Research and Educational Center in Gastroenterology and Hepatology of St Petersburg Universitetskaya Naberezhnaya, Saint Petersburg, Russia

4.

Sanofi-Aventis, Moscow, Russia

Turk J Gastroenterol 2021; 32: 750-757
DOI: 10.5152/tjg.2021.20294
Read: 269 Downloads: 83 Published: 20 September 2021

Background: Essential phospholipids (EPL) are used as adjuvant treatment in people with fatty liver disease and other chronic liver diseases. A new formulation of EPL paste was developed to improve patient compliance. The study was aimed to assess the safety, patient-reported outcomes, and impact on compliance of the new EPL paste formulation in patients with non-alcoholic fatty liver disease (NAFLD) or viral hepatitis. 

Methods: The study enrolled 147 patients (48.3% male; mean ± standard deviation (SD) age 44.8 ± 10.5 years) in the intention-to-treat population; 72.8% had NAFLD and 27.9% had viral hepatitis B (HBV) or hepatitis C (HCV). Patients received EPL paste (one 600 mg sachet 3 times daily) for 12 weeks, with 4-, 8-, and 12-week scheduled visits and a 13-week follow-up visit. Patient-reported outcomes were evaluated at 4, 8, and 12 weeks compared with baseline using dedicated Likert scales. Compliance was assessed by comparing actual versus prescribed dosing of the EPL.

Results: After 12-week treatment with EPL paste, statistically significant improvements were observed in mean ± SD Global Overall Symptom scores (from 4.21 ± 1.09 to 1.87 ± 0.91; P < .01) and overall Gastrointestinal Symptom scores (from 19.91 ± 5.74 to 11.17 ± 3.57; P < .01), compared to baseline scores. Compliance with prescribed essential phospholipid treatment was 99% throughout the 12-week treatment period.

Conclusion: Essential phospholipids paste had a favorable safety profile associated with improved gastrointestinal symptoms and with high levels of compliance in patients with NAFLD and viral hepatitis.

Cite this article as: Ivashkin VT, Maev IV, Pavlov CS, et al. Safety and effectiveness of essential phospholipids paste in patients with non-alcoholic fatty liver disease or viral hepatitis. Turk J Gastroenterol. 2021; 32(9): 750-757.

Files
EISSN 2148-5607